These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 9152970

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S.
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK.
    Cancer; 1998 Jan 15; 82(2):301-8. PubMed ID: 9445186
    [Abstract] [Full Text] [Related]

  • 8. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, Mayernik DG, Oette DH, Haynes FA, Holcenberg J.
    Am J Hematol; 1996 Apr 15; 51(4):289-95. PubMed ID: 8602629
    [Abstract] [Full Text] [Related]

  • 9. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 01; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

  • 11. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 01; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 01; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 13. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 01; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 14. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, López E, Paz-Ares L, Hitt R, García-Ribas I.
    J Natl Cancer Inst; 1995 Jun 07; 87(11):803-8. PubMed ID: 7540696
    [Abstract] [Full Text] [Related]

  • 15. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
    Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R.
    Cancer; 1999 Feb 15; 85(4):855-63. PubMed ID: 10091762
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
    Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Räth U, Poliwoda H.
    Ann Hematol; 1993 Aug 15; 67(2):75-9. PubMed ID: 8347733
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR, Southwest Oncology Group.
    Clin Cancer Res; 2001 Aug 15; 7(8):2325-9. PubMed ID: 11489808
    [Abstract] [Full Text] [Related]

  • 20. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT, Roon R, Ferguson J, Martinez L, Stidley CA, Neidhart JA.
    Biotechnol Ther; 1993 Aug 15; 4(3-4):183-95. PubMed ID: 8292969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.